Multiple sclerosis outcome and morbimortality of a Brazilian cohort patients

Arquivos de Neuro-Psiquiatria

Volumn 66, Issue 3 B, 2008, Pages 671-677

  Alves Leon, Soniza Vieira ^a,b   Malfetano, Fabíola Rachid ^b,c   Pimentel, Maria Lucia Veluttini ^b   Estrada, Claudio Luiz Duque ^b   Pereira, Valéria Coelho Santa Rita ^b   Liem, Assuncíon Martinez ^b   Novis, Sérgio Augusto Pereira ^b  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Hospital Naval Marcílio Dias

Author keywords

Brazil; Epidemiology; Morbidity; Mortality; Multiple sclerosis

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; DEMYELINATING DISEASE; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; ETHNIC GROUP; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; ONSET AGE; OUTCOME ASSESSMENT; PATIENT MONITORING; PREVALENCE; RACE DIFFERENCE; RELAPSE; REMISSION; SEX DIFFERENCE;

EID: 56049124141     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2008000500012     Document Type: Article

References (34)

1. Arnason B. The role of cytokines in multiple sclerosis. Neurology 1995;45(Suppl):S554-S555.
2. Brosnan CF, Canella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995;45(Suppl):S16-S21.
3. Ristori G, Montesperelli C, Pena A et al. Global immune disregulation in multiple sclerosis: from the adaptative response to the innate immunity. J Neuroimmunol 2000;107:216-219.
4. Carvalho A, Sant' Anna G, Liem A et al. Fine specificity of antibody responses to myelin sequences in association with HLA class II alleles in the serum of brazilian patients with multiple sclerosis. Mul Scler 2002;7:407-408.
5. Correlale J, Tenembaum SN. Myelin basic protein and myelin oligodendrocyte glycoprotein T- cell repertoire in childhood and juvenile multiple sclerosis. Mult Scler 2006;12:412-420.
6. Merkler D, Schmelting B, Czeh B, Fuchs E, Stadelmann C, Bruck W. Myelin oligodendrocyte glycoprotein-induced experimental encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult Scler 2006;12:369-374.
7. Imitola J, Chitnis T, Khoury SJ. Insights into the molecular pathogenesis in the pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 2006;63:25-32.
8. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
9. Rudick R, Antel J, Confavreux C et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40:469-479.
10. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
11. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
12. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
13. Weinshenker BG, Santrach P, Bissonet AS, et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998;51:742-747.
14. Hawkins SA, Mc Donnell GV. Benignmultiple sclerosis? Clinical course, Benign multiple long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148-152.
15. on of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult Scler 2001;7:345-347.
16. Ghezzi A. Clinical characteristics of multiple sclerosis with early onset. Neurol Sci 2004;25(Suppl):S336-S339.
17. Martinelli V, Rodegher M, Morola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004;25(Suppl):S350-S355.
18. Ribeiro D. O povo brasileiro: a formação e o sentido do Brasil. São Pau- Paulo: Companhia das Letras, 1995/1996.
19. Tilbery CP, Felipe E, Baldauf CM, Peres MF. Multiple sclerosis: clinical analysis and development of 214 cases. Arq Neuropsiquatr 1995;2:quatr 203-207.
20. Lana-Peixoto MA, Frota E, Campo GB, Botelho CM, Aragão AL. The prevalence of multiple sclerosis in Belo Horizonte. Mult Scler 2002;8(Suppl):S38.
21. Leite ACCB, Andrade C, Novis S. Esclerose múltipla no Rio de Janeiro: apresentação clínica em 51 casos. Arq Neuropsiquiatr 1990;48(Suppl):S66.
22. Oliveira EML, Annes M, Oliveira ASB, Gabbai AA. Estudo clínico de 50 pacientes acompanhados no ambulatório de neurologia UNIFESP-EPM. Arq Neuropsiquiatr 1999;57:51-55.
23. Papais-Alvarenga RM, Santos CMM, Colin DD, et al. Esclerose múltipla: influência do sexo e etnia no perfil clínico de 88 pacientes no município do Rio de Janeiro. Rev Bras Neurol 1995;31:89-98.
24. Alves-Leon SV. HLA DQB1*0602 confere susceptibilidade genética para Esclerose Múltipla numa população de pacientes afro-brasileiros da cidade do Rio de Janeiro. Tese. Rio de Janeiro, 1999.
25. Arruda WO, Scola RH, Teive HA, Werneck LC. Multiple sclerosis: report on 200 cases from Curitiba, Southern Brazil and comparison with other Brazilian series. Arq Neuropsiquiatr 2001;59:165-170.
26. Davenport CB. Multiple sclerosis from de stand point of geographic distribution and race. Arch Neurol 1992;8:51-58.
27. Alves-Leon SV, Alvarenga RP, Magalhães M, Alvarenga M, Thuler LC, Fernandez OF. Ethnicity-dependent association of HLA DRB1-DAQ1-DAB1 alleles in Brazilian multiple sclerosis patients. Acta Neurol Scand 2007;115:306-311.
28. Callegaro D, Goldbaum M, Morais L et al. The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997. Acta Neurol Scand 2001;104:208-213.
29. Brito Ferreira ML, Machado MIM, Vilela ML, et al. Epidemiologia de 118 casos de esclerose múltipla com seguimento de 15 anos no centro de referência do Hospital da Restauração de Pernambuco. Arq Neuropsiquiatr 2004;62:1027-1032.
30. Moreira MA, Felipe E, Mendes MF, Tilbery CP. Esclerose múltipla: estudo descritivo de suas formas clínicas em 302 casos. Arq Neuropsiquiatr 2000;58:460-466.
31. Bergamaschi R, Montomoli C, Candeloro E, Fratti C, Citterio A, Cosi V. Disability and mortality in a cohort of multiple sclerosis patients: a reappraisal. Neuroepidemiology 2005;25:15-18.
32. Ekestern E, Lebhart G. Mortality from multiple sclerosis in Austria 1970-2001: dynamics, trends and prospects. Eur J Neurol 2004;11:511-520.
33. Hansen HB, Henriksen NK, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-850.
34. Glad S, Nyland H, Myr K-M. Benign multiple sclerosis. Acta Neurol Scand 2006;113(Suppl):S55-S57.